News & Updates

The use of amphilimus-eluting stents (AES) in patients with diabetes mellitus undergoing percutaneous revascularization was less likely to result in target lesion or target vessel failure compared with zotarolimus-eluting stents (ZES) at 1 year, according to findings of the SUGAR trial presented at TCT 2021.

Treatment with the nonsteroidal mineralocorticoid receptor antagonist finerenone helps prevent the incidence of new-onset heart failure (HF) and improve other HF outcomes among patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), as shown in a secondary analysis of the phase III FIGARO-DKD trial.

Low levels of 25-hydroxyvitamin D seem to be correlated with arterial stiffness in patients with type 2 diabetes mellitus (T2DM), a recent study has found.

Withdrawal of beta-blocker treatment has led to increased maximal functional capacity in patients with heart failure with preserved ejection fraction (HFpEF) and chronotropic incompetence, reports a recent study, noting how use of beta-blockers deserved re-evaluation.

Patients who develop acute kidney injury (AKI) following an acute myocardial infarction (AMI) have an elevated risk of more serious kidney outcomes including persistent reductions in estimated glomerular filtration rate (eGFR), end-stage renal disease (ESRD), or renal death, according to results of the PARADISE-MI trial.